Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of oral ALS-008176 (lumicitabine) in adults hospitalized with RSV infection
2016-001653-40Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Lumicitabine arm with Placebo arm (2 arms). Primary endpoint: Antiviral activity in Part 1. Started Jun 2016; status: terminated.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-001653-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001653-40.